Fellowship Manor Medicare and Medicaid Location: 3000 Fellowship Drive, Whitehall, Pennsylvania 18052 Ratings: Phone: (610) 799-3000 |
News Archive
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
Indiana University psychologists have shown that a baby's most likely first words are based upon their visual experience, laying the foundation for a new theory of infant language learning.
Adamas Pharmaceuticals, an emerging pharmaceutical company focused on developing small-molecule therapeutics to treat neurological and infectious diseases, selected Veeva System's VBioPharma™ KOL Edition – part of the Veeva CRM suite. Selection of Veeva's SaaS solution marks an important step in Adamas' early-stage product commercialization strategy.
Scientists of the Antwerp Institute of Tropical Medicine (ITG) opened a new front against the cause of sleeping sickness. This parasite is transmitted between humans by tsetse flies. The researchers learned a bacterium living in those flies how to produce antibodies against the parasite. Application in the field is still a long way of, but the technique shows quite some promise.
Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.
› Verified 3 days ago